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Effect of glucose–insulin–potassium on Plasma
concentrations of C-reactive protein in acute
ST- Elevation Myocardial Infarction; A Randomized Clinical Trial
Maryam Hashemian1, Alireza Vakili2, Arash Akaberi3
ABSTRACT
Objective: The anti inflammatory effects of glucose–insulin–potassium (GIK) in the
management of patients with ST segment elevation myocardial infarction (STEMI) are
controversial. We aimed to evaluate anti-inflammatory effect of GIK in STEMI patients treated
with streptokinase which is not obvious up to now.
Methodology: This randomized clinical trial enrolled 72 patients who had STEMI that were
treated within 12 hours from symptom onset with a high dose of GIK (25% glucose, 50 IU of
soluble insulin per liter, and 80 m mol of potassium chloride per liter at 1 ml/kg/hour) (GIK
group) or normal saline (control group) as adjunct to thrombolytic therapy. We analyzed Plasma
concentrations of high-sensitivity C-reactive protein (HS CRP) at baseline and sequentially for
48 hours.
Results: Baseline HS CRP were significantly increased (2- to 3-fold) at 24 and 48 hours in each
group (P<0.01). There was no difference in plasma concentrations of HS CRP between GIK and
control patients (P = 0.24). Mean glucose level over 6 hours was higher in GIK group than
control group (P=0.006).
Conclusion: GIK therapy offers no anti-inflammatory effect in patients with STEMI treated with
streptokinase.
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INTRODUCTION
The effects of glucose–insulin–potassium (GIK) in
the treatment of ST segment elevation myocardial
infarction (STEMI) are controversial. Fath-Ordoubadi
et al published a meta-analysis of GIK treatment and
showed that GIK infusion could reduce in-hospital
mortality.1 The Glucose–insulin–potassium study-I
(GIPS-I) showed that GIK did not reduce mortality
in the total population, but it reduced mortality in
STEMI patients without signs of heart failure2, but
in the GIPS-II mortality did not differ between
groups.3 In CREATE-ECLA-II and DIGAMI-II,4,5 no
beneficial effects of GIK were observed. In rat model
of ischemic myocardial injury, insulin can reduce
infarct size.6
However, studies about GIK effects are ongoing.
On the other hand C-reactive protein (CRP), as an
indicator of inflammation is shown to have prognos-
tic value, in acute coronary syndromes.7-9 Throm-
bolytic efficacy and a patent infarct-related coronary
artery could be realized thorough a reduction in the
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rise of CRP.10-11 A high CRP after MI increases infarct
expansion.7,10,12 The effect of ß-blockers13 and
abciximab, is combined with a reduction of CRP,14
high CRP in rats with induced MI can increase myo-
cardial infarct size significantly.15
But, the influence of high dose GIK on CRP levels
in patients with ST-segment elevation MI treated by
intravenous thrombolytic agents has not been previ-
ously investigated. Evaluating HS CRP concentra-
tion is more precise than mortality and could com-
pare GIK therapy with conventional treatment very
well. Hence we assessed this effect of GIK in STEMI
patients treated with streptokinase.
METHODOLOGY
Study Patients: After approval from university ethic
committee, recruitment began. From September 2008
to July 2009, 74 consecutive STEMI patients were
randomized to traditional care (N = 39) or additional
GIK infusion (N = 35).We missed two patients in the
GIK group to follow up. All consecutive patients who
had 20 minutes chest pain or its equivalent, time from
symptom onset <12 hours, and had ST elevation >1
mm in >2 contiguous electrocardiographic leads were
admitted to the Coronary Care Unit of the Vaseie
General Hospital (Sabzevar, Iran).16,17
Patient with systemic infection, glucocorticoid
therapy, hypotension, congestive heart failure, crea-
tinine >2.0 mg/dL, anemia (hemoglobin <11 g/dL),
and unwilling to participate were excluded. We ob-
tained Informed consent from the participants or
their legal guardians.
Study design: The study was randomized, prospec-
tive, and triple blinded. On admission, patients were
randomized via block randomization and assigned
to the respective group by a closed envelope system.
In A group, patients received high-dose GIK infu-
sion (25% glucose, 50 IU of soluble insulin per liter,
and 80 mmol of potassium chloride per liter at 1ml/
kg/hour) as an adjunct to thrombolytic therapy (1.5
MU of streptokinase/30 to 60 minutes) [GIK group].
In B group 1 L normal saline at 60 mL/h infused in
addition to thrombolytic therapy (1.5 MU of strep-
tokinase/30 to 60 minutes) [control group].
Neither the patients nor the researcher nor the
statistical consultant knew which group called A and
which one called B group (triple blinded). GIK ad-
ministered in the hospital that initiated the
reperfusion therapy. All other medication was stan-
dard as ACC/AHA guidelines.17
Data collection: Blood was collected at baseline and
at 6, 16, 24, and 48 hours. We used an ELISA kit to
measure High-sensitivity C-reactive protein (mg/L),
[lowest detection limit 0.35 ng/mL; inter assay coef-
ficient of variation (CV), 3% to 7%; intra-assay CV,
<5%]. In each patient, total CK and CK-MB level were
measured on admission, 16 and24 hours thereafter.
In all patients, plasma concentrations of glucose and
potassium were determined before and at 6 hour af-
ter administering therapy.
Study End Points: The primary end point of the study
was plasma concentration of HS CRP, and compar-
ing between and within the control and GIK groups.
A similar approach was used in Lincroft AM and
Chaudhuri studies.18,19
Statistical analysis: Data were analyzed thorough the
Statistical Package for the Social Sciences (SPSS, ver-
sion15). Continuous variables were expressed as
mean ± SD and were compared using independent t
tests and repeated measure ANOVA (such as CK,
CK-MB and HS CRP concentration). Categorical data
were analyzed by use of chi-square or Fisher exact
test. Assuming a power of 80% and α =5%, compar-
ing plasma concentration of HS CRP over the first 48
hours could be demonstrated with a sample size of
32 patients in each group. A p value <0.05 was con-
sidered to be statistically significant.
RESULTS
Seventy two patients were enrolled into the study.
There was no significant difference between basal
data among study groups (Table-I).
The time from chest pain onset to initiation of strep-
tokinase was 4.66±3.81 hours. There was no signifi-
cant difference between this interval among study
groups (P=0.16). Glucose level at baseline was 149±61
mg/dL in controls and 168±83 mg/dL in the GIK
Table-I: Baseline characteristics of 72 patients
enrolled in clinical trial of GIK.
GIK(n=33) Control P
(n=39)
Age, Years 60±12 57±11 0.3
Sex, M/F, n 8/25 13/26 0.4
Smoker, n (%) 15(45) 17(44) 0.87
Hypertension, n (%) 7(21) 6(15) 0.52
History of CAD, n (%) 1(3) 3((8) 0.62
Glucose, mg/dL 168±83 149±61 0.25
Site of infarct, n (%)
Anterior 11(33.3) 14(36.8) 0.55
Inferior 12(36.4) 17(44.7) 0.35
Other 10(30.3) 7(18.4) 0.47
Mean peak CK,U/L 2165±149 1830±152 0.13
Mean peak CK-MB,U/L 152±11 138±12 0.30
CAD, Coronary artery disease; CK, Creatine kinase,
Significance at P<0.05
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group (P=0.25). Mean glucose level over 6 hours was
higher in GIK group (212± 139 mg/dL) than control
group (142±46 mg/dL) (P=0.006).HS CRP level
increased significantly (P<0.01) in both groups
(Figure-1).
The absolute increases in HS CRP concentrations
did not differ significantly (p=0.204) in GIK and con-
trol groups (Table-II).
There was no significant difference between groups
regarding mean admission serum CK, peak CK, peak
CK-MB levels and early peak of CK within 16 hour.
Ejection Fraction (39% G vs41% C, p=0.34) and ST
segment resolution were similar between the two
groups. (p=0.8)
DISCUSSION
Our data suggest that after acute MI, plasma HS
CRP concentrations rise, and systemic inflammation
enhances. Also GIK therapy offers no anti-inflam-
matory effect, which is corresponding to large
clinical trials that showed no effect of GIK. 3-5
In an open label study Chaudhuri et al showed that
in patients with acute ST-segment elevation myocar-
dial infarction treated with reteplase, GIK infusion
reduced levels of C-reactive protein and serum amy-
loid A and attenuated an increase in plasminogen
activator-1, which suggests that GIK has an anti in-
flammatory and profibrinolytic effect. 19 On the other
hand they maintained glucose between 80 and 200
mg/dL but our approach was not tight control of
glucose and mean glucose level over 6 hours was
higher in GIK group than control group. Therefore
the inflammatory effect of glucose could counterbal-
ance the anti-inflammatory effect of insulin and could
be the cause of difference between this study and
Chaud ‘s study with tight control of glucose.
Some studies believe that GIK can decrease in free
fatty acid concentration and promotion of glycoly-
sis. Therefore an ischemic cell needs less oxygen and
produces less toxic intermediates of free fatty acid
metabolism 20. However, while reperfusion therapy
can rescue the ischemic myocardium effectively,
treatment with GIK has less value. Although before
reperfusion therapy GIK might delay ischemic ne-
crosis to some extent, as mentioned in Fath-
Ordoubadi study.1,21
Furthermore, we should notice side effects of GIK.
Hyperglycemia, hyperkalaemia and fluid overload
can affect the potential benefits, and could be the
cause of difference between this study and Chaud ‘s
study with tight control of glucose. Hyperglycemia
and hypoglycemia in some studies had worse out-
come in both short- and long-term.22-26
Study limitations: The sample size is small and the
convenience sampling of consecutive patients as-
signed from one hospital can limit generalizability.
Furthermore, higher baseline HS CRP expressed that
our patients were referred late to the hospital and
may have led to an underestimation of the advan-
tages of GIK therapy in this study. In addition HS
CRP measurement was limited to first 48 hours.
Despite these limitations, this pilot study may be
helpful in future studies.
In conclusion, in patients with STEMI, the
inflammatory factors increase despite the standard
fibrinolytics, antithrombotic therapy and GIK infu-
sion. Thus, at least at the present time, there is no
role for GIK as adjunctive treatment with
streptokinase.
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Fig-1: HS CRP concentrations in groups.
Table-II: HS CRP concentrations in groups.
Time, Hours GIK(n=33) Control P
(n=39)
HS CRP ,mg/L 4.7±5.1 9.3±6.5
0 5.6±5.9 4.0±4.3 0.35
6 9.8±6.9 8.8±6.2 0.61
24 15.3±4.4 14.4±3.5 0.46
48 16.8±2.2 15.5±3.2 0.17
CRP, C reactive protein
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